Table 2 Characteristics of studies conducted in Africa
Variable description | (N = 456) |
|---|---|
Target size | |
Mean (SD) | 6119 (36536) |
Median (Q1, Q3) | 264 (100, 1000) |
Source register | |
ANZCTR | 4 (0.9%) |
CTRI | 15 (3.3%) |
ChiCTR | 2 (0.4%) |
326 (71.5%) | |
EU Clinical Trials Register | 22 (4.8%) |
German Clinical Trials Register | 3 (0.7%) |
ISRCTN | 18 (3.9%) |
JPRN | 5 (1.1%) |
PACTR | 53 (11.6%) |
REPEC | 7 (1.5%) |
TCTR | 1 (0.2%) |
Recruitment status | |
Authorized | 20 (4.4%) |
Not recruiting | 214 (46.9%) |
Recruiting | 222 (48.7%) |
Study type | |
Expanded access | 2 (0.4%) |
Interventional study | 270 (59.2%) |
Observational study | 184 (40.4%) |
Study design | |
Randomized | 237 (52.0%) |
Non-randomized | 21 (4.6%) |
Single group interventional study | 12 (2.6%) |
Blank | 166 (36.4%) |
Other | 20 (4.4%) |
Phase | |
N/A | 82 (28.0%) |
Phase 0 | 1 (0.3%) |
Phase 1 | 30 (10.2%) |
Phase 1/phase 2 | 5 (1.7%) |
Phase 2 | 40 (13.7%) |
Phase 2/phase 3 | 27 (9.2%) |
Phase 3 | 89 (30.4%) |
Phase 4 | 19 (6.5%) |
Retrospective flag | |
No | 76 (16.7%) |
Yes | 380 (83.3%) |
Sponsor | |
Other research/industry | 202 (44.3%) |
University | 254 (55.7%) |